arrow
P

Piero Fregatti

University of Genova
H指数:23
被引数:1,964

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Effect of dose-dense adjuvant chemotherapy in patients with node-positive early breast cancer according to estrogen receptor levels: an exploratory analysis of the GIM2 trial

根据雌激素受体水平,剂量密集型辅助化疗对淋巴结阳性早期乳腺癌患者的影响:GIM2试验的探索性分析

Breast
IF7.9
2026-09-290
OA
Dose-dense adjuvant chemotherapy in HER2-low breast cancer: An exploratory analysis of the GIM2 trial

HER2低表达乳腺癌的密集剂量辅助化疗:GIM2试验的探索性分析

Breast
IF7.9
2026-06-010
OA
Simultaneous Risk-Reducing Mastectomy and Salpingo-Oophorectomy in Patients with BRCA1 and BRCA2 Pathogenic Variants: A Single-Center Retrospective Cohort Study

BRCA1和BRCA2致病性变异患者中同时进行的减瘤性乳房切除术和输卵管卵巢切除术:一项单中心回顾性队列研究

2026-05-300
OA
BREAST AI-PLAN: Prompt-Driven AI Assistance for Breast Surgery Planning - A Retrospective Single-center Study

乳房AI计划: 乳房手术计划的提示驱动AI辅助-一项回顾性单中心研究

IN VIVO
IF1.8
2025-11-010
PRE
A Rare Case of Non-Hodgkin B-Cell Lymphoma Following Invasive Lobular Carcinoma of the Breast: A Case Report

一例继发于乳腺癌浸润性小叶癌的罕见非霍奇金B细胞淋巴瘤病例报告

2025-04-100
OA
The landscape of combining immune checkpoint inhibitors with novel Therapies: Secret alliances against breast cancer

将免疫检查点抑制剂与新型疗法相结合的景观: 对抗乳腺癌的秘密联盟

2024-11-010
OAAI
Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trial
2024-08-012
OAAI
Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies

根据晚期乳腺癌国际共识指南的内分泌耐药/敏感性分类的预后和临床影响: 来自Mammella InterGruppo (MIG) 和Gruppo Italiano Mammella (GIM) 研究的个体患者水平分析

2023-05-017
OAAI